Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
122
datasets available to search
ShareScore release 0.9.0
Dataset results
122 results for “T-cell responses”
Fig. 3 in SjTat-TPI facilitates adaptive T-cell responses and reduces hepatic pathology during Schistosoma japonicum infection in BALB/c mice
Fig. 3 Th1 immune response acter CD8+T cells blockage in sitro. a. CD3+CD8+T cells were successcullv blocked. The blocking ecciciencv was more than 99.6 %. b, c. Percentages oc CD4+IFN-γ+ (Th1) in Tat-TPI (T-TPI), TPI stimulated splenocvtes with or without CD8+T-cell blockage. Data are presented as the means ± SEM crom cour independent experiments. (*P <0.05; **P <0.01)
Fig. 2 in SjTat-TPI facilitates adaptive T-cell responses and reduces hepatic pathology during Schistosoma japonicum infection in BALB/c mice
Fig. 2 Immune responses in the draining popliteal lvmph nodes oc mice induced bv Tat-TPI (T-TPI) and TPI proteins. a and c. Percentages oc CD4+IFN-γ+ cells (Th1), CD8+IFN-γ+ cells (Tc1) analvsed bv FACS. b. The ratio oc CD4+ T cells to CD8+ T cells (CD4/CD8) in the draining popliteal lvmph nodes. Data are presented as the means ± SEM crom six mice in each group. (*P <0.05; **P <0.01)
Fig. 1 in SjTat-TPI facilitates adaptive T-cell responses and reduces hepatic pathology during Schistosoma japonicum infection in BALB/c mice
Fig. 1 Expression, puricication and identicication oc the cusion proteins Tat-TPI and TPI. a. Puricication oc two cusion proteins detected bv Protein Gel Electrophoresis. M: molecular weight marker, Lane 1: recombinant SjTat-TPI, Lane 2: recombinant SjTPI, Lane 3: the recombinant plasmid without puricication. b. Fusion proteins recognised bv His-Ab with Western blotting. Lane 1: recombinant SjTat-TPI, Lane 2: recombinant SjTPI. c. Fusion proteins recognised bv S. japonicum incected-mice serum with Western blotting. Lane 1: recombinant SjTat-TPI, Lane 2: recombinant SjTPI
Fig. 5 in SjTat-TPI facilitates adaptive T-cell responses and reduces hepatic pathology during Schistosoma japonicum infection in BALB/c mice
Fig. 5 Parasite burden and immune response were obsersed at 6 weeks acter S. japonicum incection in mice saccinated with T-TPI + IFA, TPI + IFA, IFA and PBS. a. Aserage number oc worms recosered. b. Aserage number oc eggs per gram (EPG) in the liser. c. Representatise granulomas with a single egg crom each group (100×). d. Aserage area oc single egg granulomas crom each group. e, f. Percentages oc CD3+CD4+IFN-γ+(Th1) and CD3+CD8+IFN-γ+(Tc1) gated crom CD3+ T cells analvsed bv FACS. Each bar represents the means ± SEM crom twelse mice per group. (*P <0.05; **P <0.01)
Fig. 4 T cell and antibodies responses acter three immunisations with T in SjTat-TPI facilitates adaptive T-cell responses and reduces hepatic pathology during Schistosoma japonicum infection in BALB/c mice
Fig. 4 T cell and antibodies responses acter three immunisations with T-TPI + IFA, TPI + IFA, IFA and PBS. a and b: Percentages oc CD3+CD4+IFN-γ+ (Th1) and CD3+CD8+IFN-γ+ (Tc1) gated crom CD3+ cells analvsed bv FACS. c. IgG, IgG1 and IgG2a lesels in mice sera were detected. Data are presented as the means ± SEM crom eight mice in each group. (*P <0.05; **P <0.01)
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
ClinicalTrials.gov study NCT06390319. IPD Sharing: YES. Countries: 1. Publications: 0.
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009
ClinicalTrials.gov study NCT01987349. IPD Sharing: NO. Countries: 1. Publications: 3.
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010
ClinicalTrials.gov study NCT03022396. IPD Sharing: NO. Countries: 0. Publications: 8.
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013
ClinicalTrials.gov study NCT03023176. IPD Sharing: NO. Countries: 0. Publications: 1.
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011
ClinicalTrials.gov study NCT03022422. IPD Sharing: NO. Countries: 0. Publications: 5.
Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients.
ClinicalTrials.gov study NCT06474169. IPD Sharing: NO. Countries: 1. Publications: 7.
Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT06951399. IPD Sharing: NO. Countries: 1. Publications: 1.
Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant
ClinicalTrials.gov study NCT02550639. IPD Sharing: Not stated. Countries: 2. Publications: 3.
Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection
ClinicalTrials.gov study NCT04362865. IPD Sharing: YES. Countries: 1. Publications: 3.
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012
ClinicalTrials.gov study NCT03022435. IPD Sharing: NO. Countries: 0. Publications: 3.
Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda).
ClinicalTrials.gov study NCT07158190. IPD Sharing: NO. Countries: 1. Publications: 3.
Data from: A single 17D Yellow Fever vaccination provides lifelong immunity; characterization of Yellow-Fever-specific neutralizing antibody and T-cell responses after vaccination
Introduction: Prompted by recent amendments of Yellow Fever (YF) vaccination guidelines from boost to single vaccination strategy and the paucity of clinical data to support this adjustment, we used the profile of the YF-specific CD8+ T-cell subset profiles after primary vaccination and neutralizing antibodies as a proxy for potentially longer lasting immunity. Methods and Findings: PBMCs and serum were collected in six individuals on days 0, 3, 5, 12, 28 and 180, and in 99 individuals >10 years after YF-vaccination. Phenotypic characteristics of YF- tetramer+ CD8+ T-cells were determined using class I tetramers. Antibody responses were measured using a standardized plaque reduction neutralization test (PRNT). Also, characteristics of YF-tetramer positive CD8+ T-cells were compared between individuals who had received a primary- and a booster vaccination. YF-tetramer+ CD8+ T-cells were detectable on day 12 (median tetramer+ cells as percentage of CD8+ T-cells 0.2%, range 0.07–3.1%). On day 180, these cells were still present (median 0.06%, range 0.02–0.78%). The phenotype of YF-tetramer positive CD8+ T-cells shifted from acute phase effector cells on day 12, to late differentiated or effector memory phenotype (CD45RA-/+CD27-) on day 28. Two subsets of YF-tetramer positive T-cells (CD45RA+CD27- and CD45RA+CD27+) persisted until day 180. Within all phenotypic subsets, the T-bet: Eomes ratio tended to be high on day 28 after vaccination and shifted towards predominant Eomes expression on day 180 (median 6.0 (day 28) vs. 2.2 (day 180) p = 0.0625), suggestive of imprinting compatible with long-lived memory properties. YF-tetramer positive CD8+ T-cells were detectable up to 18 years post vaccination, YF-specific antibodies were detectable up to 40 years after single vaccination. Booster vaccination did not increase titers of YF-specific antibodies (mean 12.5 vs. 13.1, p = 0.583), nor induce frequencies or alter phenotypes of YF-tetramer+ CD8+ T-cells. Conclusion: The presence of a functionally competent YF-specific memory T-cell pool 18 years and sufficient titers of neutralizing antibodies 35–40 years after first vaccination suggest that single vaccination may be sufficient to provide long-term immunity.
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
ClinicalTrials.gov study NCT05032820. IPD Sharing: YES. Countries: 1. Publications: 0.
Data from: A single 17D Yellow Fever vaccination provides lifelong immunity; characterization of Yellow-Fever-specific neutralizing antibody and T-cell responses after vaccination
Open the record for dataset details and reuse information.
Iron boosts anti-tumor type 1 T-cell responses and anti-PD1 immunotherapy
GEO Series GSE262545. Mus musculus. 8 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.